6 unknown. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Unknown 6 |
| Phase 2 | 1 | Unknown 1 |
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2. - Immunogenicity, Safety | Phase 3 | Unknown | Stemirna Therapeutics | 600 | 2022-10-19 | 2023-01-17 |
| New Generation mRNA Booster Vaccine Against Emerging VOCs SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated - Immunogenicity, Efficacy | Phase 3 | Unknown | Stemirna Therapeutics | 2000 | 2022-10-01 | 2023-04-12 |
| Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients Advixa (Adalimumab) - Pharmacokinetics, Safety | Phase 2 / Phase 3 | Unknown | Institute for Developing Science and Health Initiatives, Bangladesh | 200 | 2021-06-02 | 2022-07-07 |
| Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis. Auris-Sedina, Otosynalar® - Otitis, Efficacy | Phase 3 | Unknown | Laboratorios Osorio de Moraes Ltda. | 188 | 2009-12-01 | 2009-08-27 |
| Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety Passiflora, Crataegus e Salix - Anxiety, Efficacy | Phase 3 | Unknown | Ativus Farmaceutica Ltda | 124 | 2009-09-01 | 2009-07-24 |
Anxiety Disorders (1) · Arthritis, Rheumatoid (1) · Carcinoma, Ovarian Epithelial (1) · Lymphoma, Follicular (1) · Otitis (1)
Immune System Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Adnexal Diseases (1) · Arthritis (1) · Autoimmune Diseases (1) · Carcinoma (1) · Connective Tissue Diseases (1) · Ear Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1)
Adalimumab (1) · apatinib (1) · fluzoparib (1)
Stemirna Therapeutics (2) · Anhui Provincial Hospital (1) · Ativus Farmaceutica Ltda (1) · Institute for Developing Science and Health Initiatives, Bangladesh (1) · Laboratorios Osorio de Moraes Ltda. (1)
Brazil (2) · Laos (2) · Bangladesh (1)
Elie Fiss (2) · Mayfong Mayxay, doctor (2) · Ying Zhou, MD (1) · Zannat Kawser, M.Phil. (1)